trial

Cognitive Behavior Therapy for Patients With Psychoses.

NCTId NCT03501888
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 16 (actual)
Sponsored by Karolinska Institutet
Primary completion 2016-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2015-10
Primary completion
2016-08-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Cognitive Behavior TherapyAcceptance and Commitment Therapy

Sponsors

Karolinska InstitutetLead Sponsor
Region StockholmCollaborator

Investigators

1
Helena Fatouros-Bergman, PhDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
16
Phase
NA
Primary Completion Date
2016-08-31
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Behavior Therapy
drug
Acceptance and Commitment Therapy
drug
lead_sponsor
Karolinska Institutet
company
collaborator
Region Stockholm
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Helena Fatouros-Bergman, PhD
person